DDIs in HIV Webinar: Real Cases, Expert Insights

José Moltó is clinical physician in the HIV Clinic of the Hospital Universitari Germans Trias i Pujol in Badalona, Spain. He obtained is MD from the University of Alicante in 1996, and completed his internal medicine training in the Hospital General Universitario de Elche (Alicante). Since his very early medicine studies, Dr. Moltó was interested in infectious diseases, particularly in HIV infection. He joined the HIV Clinic of the Hospital Universitari Germans Trias i Pujol in 2002, and he obtained his PhD degree from the Universitat Autònoma de Barcelona in 2008. He is committed with HIV research with special interest in clinical pharmacology of antiretroviral treatment, including population pharmacokinetics and drug-drug interactions.

Catia Marzolini obtained a degree in Pharmacy followed by a PhD in Clinical Pharmacology at the University of Lausanne, Switzerland. She completed a post-doctoral fellowship within the Division of Clinical Pharmacology at Vanderbilt University, Nashville, USA.

Catia Marzolini is an Associate Professor at the University Hospital of Basel. Her main research interest is the pharmacology of antiretroviral drugs with a focus on drug-drug interactions, pharmacokinetics in special populations and prescribing issues in elderly people living with HIV. She has authored/co-authored more than 130 publications. Catia Marzolini is also the scientific lead of the University of Liverpool HIV and COVID-19 drug interactions websites. She serves on the European AIDS Clinical Society (EACS) guidelines committee where she co-chairs the drug-drug interaction section and is a member of the scientific board of the Swiss HIV Cohort Study.

Juan Ambrosioni MD, Ph.D. He is a specialist at the Infectious Diseases Service of Hospital Clinic, Barcelona, and Assistant Professor of Medicine at the University of Barcelona, since 2014. He is an ID specialist of the University of Buenos Aires, Argentina and the University of Geneva, Switzerland. Juan Ambrosioni is author of more than 130 peer-reviewed scientific articles indexed in PubMed (more than 40 as first, last or corresponding author), and more than 30 book chapters. He is the principal investigator of national and international projects in the field of HIV infection, co-infections and opportunistic infections. His main research fields are currently focused on antiretroviral therapy, primary HIV infection and tuberculous meningitis. During the COVID-19 pandemic, he has been involved in clinical management of COVID-19 cases including those presented in people living with HIV. He is a member of the ‘Opportunistic Infections and COVID-19’ panel of the European AIDS Clinical Society (EACS) Guidelines.

Ezequiel Córdova MD, is an infectious diseases and clinical pharmacology specialist at the University of Buenos Aires, Argentina. He works as an infectious diseases specialist at the Infectious Diseases Unit of Hospital Cosme Argerich and as HIV clinical investigator in Fundación IDEAA, Buenos Aires, Argentina. He is Assistance Professor of Infectious Diseases at the University of Buenos Aires, Argentina. He is also associate editor for Actualizaciones en SIDA e Infectologia Journal (ASEI). He is member of the HIV and STI Comission of the Sociedad Argentina de Infectologia. Furthermore, he is the Coordinator of the “Pharmacology of Antiretroviral Drugs” chapter in the Argentinian Guidelines on antiretroviral treatment. His main research interests are TB/HIV coinfection, clinical pharmacology of antiretroviral treatment, drug-drug interactions and, antimicrobial resistance.

Gordana Dragovic Lukic is a MD, Ph.D., specialist in clinical pharmacology. She obtained her MD in 1997 and completed her specialisation in clinical pharmacology in 2003, both at the School of Medicine, University of Belgrade. In 2000 she has joined the HIV/AIDS Center of the Infective diseases clinic, University teaching hospital in Belgrade, Serbia. Dr. Gordana obtained her Ph.D. degree in 2008 at the School of Medicine, University of Belgrade. Since 2015, she is appointed as Associate Professor of Pharmacology and Clinical Pharmacology at the University of Belgrade, Serbia. Currently, she is a Head of the Pharmacokinetic Unit of the antiretroviral drugs at the School of Medicine, University of Belgrade. The research activity of Gordana Dragovic Lukic has focused mainly on the clinical pharmacology of antiretroviral drugs, population pharmacokinetics, pharmacogenomics of antiretrovirals and drug-drug interactions.